Small molecule inhibitors of BRAF in clinical trials

Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 22; no. 2; pp. 789 - 792
Main Authors Zambon, Alfonso, Niculescu-Duvaz, Ion, Niculescu-Duvaz, Dan, Marais, Richard, Springer, Caroline J
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Ltd 15.01.2012
Elsevier
Subjects
Biological and medical sciences
BRAF protein
chemistry
Clinical candidate
clinical trials
Clinical Trials as Topic
Humans
Kinase inhibitor
Medical sciences
melanoma
Melanoma - drug therapy
Melanoma - metabolism
Molecular Weight
Pharmacology. Drug treatments
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins B-raf - metabolism
Structure-Activity Relationship
BRAF protein
Kinase inhibitor
Clinical candidate
Human
Clinical trial
Inhibitor
Small molecule
Protein
Online AccessGet full text

Cover

More Information
Summary:Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.
Bibliography:http://dx.doi.org/10.1016/j.bmcl.2011.11.060
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Feature-1
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2011.11.060